Zolbetuximab
Zolbetuximab is a chimeric monoclonal antibody targeting Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed on gastric and gastroesophageal junction tumor cells, that mediates antitumor activity through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) upon CLDN18.2 binding. It is approved in combination with chemotherapy for first-line treatment of HER2-negative, CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Its targetable tumor-selective expression makes CLDN18.2 a novel antigen in upper gastrointestinal malignancies.
Area Terapeutik
Mekanisme Kerja
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Zolbetuximab is a chimeric monoclonal antibody targeting Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed on gastric and gastroesophageal junction tumor cells, that mediates antitumor activity through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) upon CLDN18.2 binding. It is approved in combination with chemotherapy for first-line treatment of HER2-negative, CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Its targetable tumor-selective expression makes CLDN18.2 a novel antigen in upper gastrointestinal malignancies.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Zolbetuximab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109427. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zolbetuximab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zolbetuximab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zolbetuximab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zolbetuximab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zolbetuximab"></drugfyi-drug>